Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer?

被引：2

作者：

Patel, Shruti R. ^{[1
,2
]}

Neal, Joel W.

机构：

[1] Stanford Univ, Stanford Canc Inst, Dept Med, Div Med Oncol, Palo Alto, CA USA

[2] Stanford Univ, Stanford Canc Inst, Dept Med Oncol, Palo Alto, CA 94305 USA

来源：

TRANSLATIONAL LUNG CANCER RESEARCH | 2023年 / 12卷 / 07期

关键词：

Osimertinib; epidermal growth factor receptor (EGFR); non-small cell lung cancer (NSCLC); adjuvant; ADAURA;

D O I：

10.21037/tlcr-23-273

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1631 / 1635

页数：5

共 14 条

[1]

[Anonymous], 2020, Cancer Discov, V10, pOF7, DOI 10.1158/2159-8290.CD-ND2020-010

[2]

astrazeneca, Tagrisso demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial

[3]

Chen LN, 2022, J CLIN ONCOL, V40

[4] Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment [J].

Duma, Narjust ;

Santana-Davila, Rafael ;

Molina, Julian R. .

MAYO CLINIC PROCEEDINGS, 2019, 94 (08) :1623-1640

[5]

fda cder, TAGRISSO FDA LABEL

[6] Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial [J].

Felip, Enriqueta ;

Altorki, Nasser ;

Zhou, Caicun ;

Csoszi, Tibor ;

Vynnychenko, Ihor ;

Goloborodko, Oleksandr ;

Luft, Alexander ;

Akopov, Andrey ;

Martinez-Marti, Alex ;

Kenmotsu, Hirotsugu ;

Chen, Yuh-Min ;

Chella, Antonio ;

Sugawara, Shunichi ;

Voong, David ;

Wu, Fan ;

Yi, Jing ;

Deng, Yu ;

McCleland, Mark ;

Bennett, Elizabeth ;

Gitlitz, Barbara ;

Wakelee, Heather .

LANCET, 2021, 398 (10308) :1344-1357

[7] Mechanisms and management of 3rd-generation EGFR-TKI resistance in advanced non-small cell lung cancer (Review) [J].

He, Jingyi ;

Huang, Zhengrong ;

Han, Linzhi ;

Gong, Yan ;

Xie, Conghua .

INTERNATIONAL JOURNAL OF ONCOLOGY, 2021, 59 (05)

[8] Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial [J].

Herbst, Roy S. ;

Wu, Yi-Long ;

John, Thomas ;

Grohe, Christian ;

Majem, Margarita ;

Wang, Jie ;

Kato, Terufumi ;

Goldman, Jonathan W. ;

Laktionov, Konstantin ;

Kim, Sang-We ;

Yu, Chong-Jen ;

Vu, Huu Vinh ;

Lu, Shun ;

Lee, Kye Young ;

Mukhametshina, Guzel ;

Akewanlop, Charuwan ;

de Marinis, Filippo ;

Bonanno, Laura ;

Domine, Manuel ;

Shepherd, Frances A. ;

Urban, Damien ;

Huang, Xiangning ;

Bolanos, Ana ;

Stachowiak, Marta ;

Tsuboi, Masahiro .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (10) :1830-+

[9] Lung Adjuvant Cisplatin Evaluation: A pooled analysis by the LACE collaborative group [J].

Pignon, Jean-Pierre ;

Tribodet, Helene ;

Scagliotti, Giorgio V. ;

Douillard, Jean-Yves ;

Shepherd, Frances A. ;

Stephens, Richard J. ;

Dunant, Ariane ;

Torri, Valter ;

Rosell, Rafael ;

Seymour, Lesley ;

Spiro, Stephen G. ;

Rolland, Estelle ;

Fossati, Roldano ;

Aubert, Delphine ;

Ding, Keyue ;

Waller, David ;

Le Chevalier, Thierry .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (21) :3552-3559

[10] Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].

Postmus, P. E. ;

Kerr, K. M. ;

Oudkerk, M. ;

Senan, S. ;

Waller, D. A. ;

Vansteenkiste, J. ;

Escriu, C. ;

Peters, S. .

ANNALS OF ONCOLOGY, 2017, 28 :1-21

← 1 2 →